Advertisement

Interferon-α2b in Chronic Myelogenous Leukemia: Experience with Two Treatment Regimen

  • M. Freund
  • P. von Wussow
  • F. Hild
  • F. Buchholz
  • Th. Buhr
  • J. Tischler
  • R. Eisert
  • O. Koch
  • S. LeBlanc
  • B. Blessmann
  • S. Stiller
  • H. D. Kleine
  • G. Exeriede
  • W. Hiddemann
  • H. Link
  • H. Wilke
  • C. Fonatsch
  • H. Poliwoda
Conference paper

Abstract

Interferons α, ß, and γ suppress stem cell proliferation in normal bone marrow and in bone marrow from patients with chronic myelogenous leukemia (CML) [1–6]. Based on these in vitro data, several studies have been done in CML patients with human leukocyte interferon (IFN) [7], lymphoblast IFN-α [8], and recombinant IFN-α [9–13] or IFN-γ [14]. In these studies, the potential of IFN to induce partial or complete hematologic remissions and cytogenetic ones in some patients was demonstrated. Although the basic effect of IFN-α is well established in CML, the optimal dose schedule and combination with chemotherapy or other cytokines is still unclear. Against this background we report on two subsequent studies with IFN treatment of CML.

Keywords

Blast Crisis Cytogenetic Response Pulmonal Alveolar Proteinosis Hematologic Remission Cytogenetic Remission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Talpaz M, Spitzer G, Hittelman W, Kantarjian H, Gutterman JU (1986) Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients. Exp Hematol 14:668–671PubMedGoogle Scholar
  2. 2.
    Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin By (1983) Comparative analysis of the influences of human interferon gamma on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage ( CFU-GM) progenitor cells. J Immunol 131:1300–1305PubMedGoogle Scholar
  3. 3.
    Lu L, Welte K, Gabrilove JL, Hangoc G, Bruno E, Hoffmann R, Broxmeyer HE (1986) Effects of recombinant human tumor necrosis factor alpha, recombinant human gamma interferon, and prostaglandin E on colony formation of human hematopoietic progenitor cells stimulated by natural human pluripotent colony stimulating factor, pluripoietin. Cancer Res 46:4357–4361PubMedGoogle Scholar
  4. 4.
    Neumann HA, Fauser AA (1982) Effect of interferon on pluripotent hemopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp Hematol 10:587–590PubMedGoogle Scholar
  5. 5.
    Oladipupo-Williams CK, Svet-Moldavskaya I, Vilcek J, Ohnuma T, Holland JD (1981) Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous granulocytic progenitor cells. Oncology 38:356–360CrossRefGoogle Scholar
  6. 6.
    Carlo-Stella C, Cazzola M, Ganser A, Bergamaschi G, Pedrazzoli P, Hoelzer D, Ascari E (1988) Synergistic antiproliferative effect of recombinant interferon gamma with recombinant interferon-α on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-MK, BFU-E, and CFU-GM). Blood 72:1293–1299PubMedGoogle Scholar
  7. 7.
    Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J (1987) Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280–1288PubMedGoogle Scholar
  8. 8.
    Schmidt H, Steinke B, Freese G, Gehr C, Gekeler V, Zinser R (1989) Interferon alpha in the treatment of myeloproliferative diseases:differences in response rate between untreated patients and patients pretreated with busulfan ( Abstract ). Blut 59:266–266CrossRefGoogle Scholar
  9. 9.
    Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314:1065–1069PubMedCrossRefGoogle Scholar
  10. 10.
    Niederle N, Kloke O, May D, Becher R, Osieka R, Schmidt CG (1987) Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b. Invest New Drugs 5:19–25CrossRefGoogle Scholar
  11. 11.
    Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F (1988) Interferon alpha-2b as therapy for Ph1-positive chronic myelogenous leukemia:A study of 82 patients treatment with intermittent or daily administration. Blood 72:642–647PubMedGoogle Scholar
  12. 12.
    Bergsagel DE, Haas RH, Messner HA (1987) Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Invest New Drugs 5:9–17CrossRefGoogle Scholar
  13. 13.
    Ozer H, Mick R. Testa J, Arthur D, Cooper R, Pettenati M, Rao K, Peterson BA, Schiffer C, Bloomfield CD (1989) Subcutaneous a-interferon (αIFN) produces clinical and cytogenetic remissions in untreated chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) (Abstract). Mol Biother [Suppl] 1:A 76Google Scholar
  14. 14.
    Kurzrock R, Talpaz M, Kantarjian H, Walters R,Saks S, Trujillo JM, Gutterman JU (1987) Therapy of chronic myelogenous leukemia with recombinant interferon gamma. Blood 70:943–947PubMedGoogle Scholar
  15. 15.
    Freund M, Von Wussow P, Diedrich H, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, Poliwoda H (1989) Recombinant human interferon (IFN) alpha 2-b in chronic myelogenous leukaemia:dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72:350–356PubMedCrossRefGoogle Scholar
  16. 16.
    Fonatsch C, Schaadt M, Kirchner H, Diehl V (1980) A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma Lines. Int J Cancer 26:749–756PubMedCrossRefGoogle Scholar
  17. 17.
    Friche E, Hansen MM, Wieslander S (1988) Refractoriness to α-interferon (intron A) in previously chemotherapy-treated patients with chronic myelocytic leukaemia. Eur J Haematol 40:305–308PubMedCrossRefGoogle Scholar
  18. 18.
    Guilhot F, Tanzer J, Brizard A, Dreyfus B, Huret JL, Desmaret MC, Briaut S (1988) Treatment of chronic myelocytic leukaemia with recombinant alpha interferon and hydroxyurea. Presse Med 17:1494–1494PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • M. Freund
  • P. von Wussow
  • F. Hild
  • F. Buchholz
  • Th. Buhr
  • J. Tischler
  • R. Eisert
  • O. Koch
  • S. LeBlanc
  • B. Blessmann
  • S. Stiller
  • H. D. Kleine
  • G. Exeriede
  • W. Hiddemann
  • H. Link
  • H. Wilke
  • C. Fonatsch
  • H. Poliwoda

There are no affiliations available

Personalised recommendations